Latest filing published 26 Jan 2024 for Rain Oncology Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by Aaron I. Davis span 5 companies, the busiest being Mirati Therapeutics, Inc., iTeos Therapeutics, Inc. and Rain Therapeutics Inc. The record holds 11 filings, for trades running from 17 November 2021 to 26 January 2024.
The open-market side counts 2 purchases for €6.4M alongside 3 sales for €4.8M. Taken together, the purchases exceed the sales by €1.6M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants.
The record was last updated on 26 January 2024 with a transaction in Rain Therapeutics Inc. The most recent open-market purchase was published on 8 November 2022, 1,440 days ago. Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations